Theralase® closed a non-brokered private placement, raising approximately CAD 310,200 by issuing 1,034,002 units at CAD 0.30 each. Proceeds will fund Phase II bladder cancer trials, Rutherrin® development, working capital, and general corporate use.

Theralase®’s Cool Laser Therapy improved motor and non-motor functions in Parkinson’s patients in a triple-blind clinical study, showing enhanced cognition, neurovascular health, and movement, supporting its potential as a non-invasive, drug-free treatment.

Theralase® reported that Rutherrin®, combined with Metformin and radiation, eliminated Non-Hodgkin’s Lymphoma in an animal model. This trimodal therapy showed tumor regression and survival benefits, supporting its promise in treating aggressive lymphomas.

Theralase® validated University of Manitoba research showing Ruvidar™ is safe and effective against HSV-1. Topical treatment healed lesions in four days, supporting its potential as a herpes therapeutic and clinical candidate.

Theralase® validated Ruvidar™ as safe and effective against HSV-1 in mice, with complete lesion healing in four days, supporting its potential for clinical use and advancement toward human trials.

Theralase® announced University of Manitoba research showing Ruvidar™ is more effective than acyclovir in inhibiting HSV-1 post-infection, even without light, and offers enhanced antiviral effects in combination therapy.

Theralase®’s bladder cancer treatment data was selected for podium presentation at the 2025 AUA Annual Meeting. Interim results show strong safety and efficacy, supporting Ruvidar™ as a breakthrough therapy option.

V.TLT | December 9, 2024 Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®’s bladder cancer treatment TORONTO, ON / December 9, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites (“CSSs“) for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio). The Principal Investigators (“PIs“) for the Theralase® clinical study at the new CSSs are as follows: Associated Medical Professionals of NY – Ilija Aleksic, MD Dr. … Read More

V.TLT | December 5, 2024 St. Joseph’s Healthcare Hamilton is the latest Canadian clinical study site for clinical investigation of Theralase®’s Anti-Cancer Therapy for the treatment of bladder cancer TORONTO, ON / December 5, 2024 / Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched a new Clinical Study Site (“CSS“) for its bladder cancer clinical study; specifically, St. Joseph’s Healthcare Hamilton (Hamilton, Ontario, Canada). Theralase®’s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System (“TLC-3200“) is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin (“BCG“)-Unresponsive Non-Muscle Invasive Bladder Cancer (“NMIBC“) Carcinoma In-Situ (“CIS“) with or without resected … Read More

TORONTO, ON / November 27, 2024 / Theralase® Technologies Inc. (“ Theralase® ” or the “ Company “) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses has released the Company’s unaudited condensed consolidated interim financial statements for the nine-month period ended September 30, 2024. (“ Financial Statements “). Theralase® will be hosting a conference call on Wednesday December 4 th at 11:00 am ET , which will include a presentation of the financial and operational results for the nine-month period ended September 30, 2024. Questions are welcome. To ensure Theralase® has time to review and properly address them during the call, please send them in advance to mperraton@theralase.com . Zoom Meeting Link: https://us02web.zoom.us/j/84816819001 Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) – not required for those attending by Zoom. An archived version will be available on … Read More